Statistics from Altmetric.com
The points below highlight changes in marketing authorisations (MAs) that may have a significant impact on veterinary surgeons’ prescribing decisions.
New marketing authorisations
New marketing authorisations relevant to veterinary surgeons in the UK that were issued or published in September 2020 are listed in Table 1.
Of those products listed, the VMD draws attention to:
• Draxxin Plus 100 mg/ml + 120 mg/ml solution for injection for cattle is the first product containing a fixed combination of the active substances tulathromycin and ketoprofen for use in cattle. The product is indicated for ‘treatment of bovine respiratory disease associated with pyrexia due to Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis susceptible to tulathromycin’.
Table 1 also indicates where a public assessment report should become available for a product. Where available, links to these reports are accessible by clicking on the relevant product on the VMD’s Product Information Database www.gov.uk/check-animal-medicine-licensed
The European Medicines Agency publishes European Public Assessment Reports for every veterinary medicine that is authorised through a centralised procedure. Links to these reports are accessible at www.ema.europa.eu
There may be a delay between the issuing of a marketing authorisation to a company and the product being placed on the market.
Changes to marketing authorisations
(1) AVINEW NEO effervescent tablet for chickens (Newcastle disease virus) (Boehringer Ingelheim Animal …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.